Prostate Cancer


FDA Approves Xtandi for Treatment of Castration-resistant Prostate Cancer (07-17-2018)

On July 13, 2018, the Food and Drug Administration approved Xtandi (enzalutamide) for patients with castration-resistant prostate cancer (CRPC).  This approval broadens the indicated patient population to include patients with both non-metastatic CRPC... Continue Reading

Immediate vs Delayed Androgen Deprivation Therapy in Prostate Cancer (05-1-2018)

CancerConnect News: There is an ongoing discussion about the optimal timing of using androgen deprivation therapy (ADT) in men with prostate cancer who have relapsed based on a rising prostate-specific antigen (PSA) and in men with early stage prostate... Continue Reading

Xtandi® A New Standard Treatment for Men with Non-Metastatic Castration-Resistant Prostate Cancer? (02-22-2018)

CancerConnect News:  Results from the Phase 3 PROSPER clinical trial in patients with non-metastatic Castration-Resistant Prostate Cancer (CRPC) were released this week at the 2018 Genitourinary Cancers Symposium in San Francisco and demonstrate that... Continue Reading

Erleada is The First Treatment for Non-metastatic Castration-resistant Prostate Cancer (02-19-2018)

CancerConnect News:  Men who are being treated with androgen deprivation therapy (ADT) and see their prostate specific antigen (PSA) levels begin to increase have a new treatment option. The U.S. Food and Drug Administration (FDA) has approved Erleada... Continue Reading

Myriad’s myRisk® Hereditary Cancer Test Finds More Than 12 Percent of Men with Prostate Cancer Carry an Inherited Genetic Mutation (02-14-2018)

Myriad Genetics a leader in molecular diagnostics and personalized medicine, announced today that results from a large 1,162 patient study will be featured during the poster presentation at the 2018 Genitourinary Cancer Symposium in San Francisco, Calif. ... Continue Reading

Two Advances in Prostate Cancers You Might Not Know About (09-8-2017)

Prostate cancer isn’t just about men, and it may be inherited. A recent study led by Peter Nelson, MD (Fred Hutchinson Cancer Research Center) has shown that 12% of advanced prostate cancers may be caused by 16 different heritable genes. That means... Continue Reading

Shorter Radiation Schedule Effective in Low-Risk Prostate Cancer (03-9-2016)

Men with low-grade prostate cancer have the same long-term outcomes when they are treated with a shorter radiation schedule, compared to those treated with a longer, conventional radiation schedule. These results were recently presented at the 2016 annual... Continue Reading

Zytiga Approved for Prostate Cancer (05-4-2011)

The US Food and Drug Administration (FDA) has approved Zytiga™ (abiraterone acetate) for the treatment of advanced prostate cancer. The approval came two months earlier than expected. Prostate cancer is a hormonally sensitive disease that can often... Continue Reading

Intermittent Hormone Therapy Effective for Prostate Cancer (04-28-2011)

For men who experience a PSA recurrence (rise in prostate-specific antigen levels) after radiation therapy for prostate cancer, hormone therapy given intermittently (with breaks) appears to be as effective as hormone therapy given continuously. These... Continue Reading

Exercise May Lower Risk of Death Among Men with Prostate Cancer (01-13-2011)

Physical activity may improve survival among men diagnosed with prostate cancer. These findings were reported in the Journal of Clinical Oncology. Exercise and its relationship to patient quality of life, cancer prevention, and impact on treatment and... Continue Reading

Next Page »